Niche Diagnostics Anchor Molecular specializes in quality controls and reference materials for molecular testing, with a focus on cfDNA and ctDNA liquid biopsy diagnostics. Sales opportunities exist in labs and research centers expanding liquid biopsy panels and seeking reliable QC materials to improve assay accuracy.

Recent Product Launch The September 2025 launch of BCR-ABL1 Control Panels creates an entry point for cross-sell to laboratories conducting hematologic malignancy testing and MRD monitoring, offering expanded QC solutions and compatibility with existing workflows.

Growable Revenue Band With reported revenue between one and ten million and a lean team, there is potential to upsell bundled QC solutions, standards, and reference materials to small to mid-size molecular labs that are scaling their liquid biopsy programs.

Digital & Partnerships Active use of e-commerce and marketing tools (Shopify, WooCommerce, Sendinblue, Calendly) enables scalable outbound campaigns and online ordering. Sales opportunities include onboarding more labs via digital channels and leveraging partnerships for education and trials.

Competitive Positioning Operating in a market with established players like Qiagen, Bio-Rad, and Illumina, Anchor Molecular can differentiate by offering specialized QC materials for cfDNA/ctDNA and cost-effective access to high-quality controls, targeting labs seeking to optimize accuracy and reduce downstream retests.